Your browser doesn't support javascript.
loading
The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT).
Sohn, Eric J; Goralsky, Julia A; Shay, Jerry W; Min, Jaewon.
Afiliación
  • Sohn EJ; Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Goralsky JA; Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Shay JW; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9039, USA.
  • Min J; Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA.
Cancers (Basel) ; 15(7)2023 Mar 23.
Article en En | MEDLINE | ID: mdl-37046606
ABSTRACT
As detailed by the end replication problem, the linear ends of a cell's chromosomes, known as telomeres, shorten with each successive round of replication until a cell enters into a state of growth arrest referred to as senescence. To maintain their immortal proliferation capacity, cancer cells must employ a telomere maintenance mechanism, such as telomerase activation or the Alternative Lengthening of Telomeres pathway (ALT). With only 10-15% of cancers utilizing the ALT mechanism, progress towards understanding its molecular components and associated hallmarks has only recently been made. This review analyzes the advances towards understanding the ALT pathway by (1) detailing the mechanisms associated with engaging the ALT pathway as well as (2) identifying potential therapeutic targets of ALT that may lead to novel cancer therapeutic treatments. Collectively, these studies indicate that the ALT molecular mechanisms involve at least two distinct pathways induced by replication stress and damage at telomeres. We suggest exploiting tumor dependency on ALT is a promising field of study because it suggests new approaches to ALT-specific therapies for cancers with poorer prognosis. While substantial progress has been made in the ALT research field, additional progress will be required to realize these advances into clinical practices to treat ALT cancers and improve patient prognoses.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos